CareDx Q3 Revenue Jumps 39%; Raises FY26 Revenue, EBITDA Guidance; Stock Up
CareDx (CDNA) reported Q3 revenue of $139M, up 39% YoY, with testing services revenue rising 65%. The company raised FY26 revenue guidance to $520M-$530M and adjusted EBITDA to $90M-$100M. Shares rose 14% in pre-market trading.
How this was made
The 30-second read
Why it matters
The article provides a fresh Q3 financial print and explicit FY26 guidance increases, plus program progress toward commercial readiness and additional clinical evidence for NavDx and AlloSure Kidney.
Market read
Traders can update positions based on the raised FY26 revenue and adjusted EBITDA ranges and the reported acceleration in Testing Services revenue and volume.
What to watch
Investors may focus on whether Testing Services growth and adjusted EBITDA margin expansion can persist after acquisitions/divestitures, and how CLIA readiness progress translates into revenue ramp.
Background
CareDx is a precision medicine diagnostics company focused on transplant and specialty oncology, with molecular testing and patient/digital solutions.
Ticker impact
CareDx reported Q3 revenue up 39% to $139M and raised FY26 revenue to $520M-$530M plus adjusted EBITDA to $90M-$100M.
Likely upward bias as the market reprices FY26 growth and profitability expectations following the guidance increase.
The article is a first-disclosed earnings and guidance update with specific revenue and adjusted EBITDA ranges, alongside a large same-day premarket jump.
Market effects
Reinforces demand momentum in transplant and oncology diagnostics testing services, potentially improving sentiment toward precision medicine diagnostics peers.
Limited, primarily US small/mid-cap biotech sentiment.
Low, company-specific guidance and clinical program updates.
Counterpoint
The stock’s move may be driven by near-term guidance optics, while longer-term commercial adoption timelines for AlloHeme and HistoMap Kidney remain execution-dependent.
Key entities
- companyCareDx, Inc.
Precision medicine diagnostics company reporting Q3 results and raising FY26 revenue and adjusted EBITDA guidance.
- programNavDx
CareDx testing offering with expanded clinical evidence described in the article.
- programAlloHeme
Program advanced toward planned commercial launch in Q1 2027, targeting CLIA readiness by year-end 2026.
- programHistoMap Kidney
Program targeting broader commercial availability in 2027, targeting CLIA readiness by year-end 2026.
- programAlloSure Kidney
Program with new KOAR registry data highlighted for risk identification when biopsy interpretation is difficult.
